BRKR Stock Overview
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Bruker Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$72.52 |
52 Week High | US$74.94 |
52 Week Low | US$48.42 |
Beta | 1.19 |
1 Month Change | 7.61% |
3 Month Change | 9.41% |
1 Year Change | 7.14% |
3 Year Change | 45.74% |
5 Year Change | 137.07% |
Change since IPO | 214.45% |
Recent News & Updates
Recent updates
Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching
Jan 17Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Dec 30Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?
Oct 16Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching
Oct 03Estimating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)
Sep 19Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Sep 05Bruker Corporation: Upside Is Limited From Here
Aug 24Bruker declares $0.05 dividend
Aug 12Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching
Jul 12Bruker announces three new GHz NMR systems orders
Jul 11Here's Why We Think Bruker (NASDAQ:BRKR) Might Deserve Your Attention Today
Jun 29Calculating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)
Jun 15Here's Why Bruker Is A Strong Buy
Jun 09Bruker (NASDAQ:BRKR) Could Easily Take On More Debt
Jun 02Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Apr 12Here's Why I Think Bruker (NASDAQ:BRKR) Might Deserve Your Attention Today
Mar 28Calculating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)
Mar 15These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Safely
Feb 17Bruker Corporation: Best Near-Term Tech Instruments Stock For Price Gains
Jan 30What Is Bruker Corporation's (NASDAQ:BRKR) Share Price Doing?
Jan 05Here's Why I Think Bruker (NASDAQ:BRKR) Is An Interesting Stock
Dec 21At US$79.07, Is It Time To Put Bruker Corporation (NASDAQ:BRKR) On Your Watch List?
Sep 30Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching
Sep 15Bruker's Renewed Focus On Growth Has Lit A Fire Under The Shares
Sep 08A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Aug 30Bruker (NASDAQ:BRKR) Could Easily Take On More Debt
Aug 03Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jun 24Shareholder Returns
BRKR | US Life Sciences | US Market | |
---|---|---|---|
7D | 1.2% | 1.7% | 1.7% |
1Y | 7.1% | -11.2% | -9.6% |
Return vs Industry: BRKR exceeded the US Life Sciences industry which returned -11.2% over the past year.
Return vs Market: BRKR exceeded the US Market which returned -9.6% over the past year.
Price Volatility
BRKR volatility | |
---|---|
BRKR Average Weekly Movement | 4.6% |
Life Sciences Industry Average Movement | 11.7% |
Market Average Movement | 6.7% |
10% most volatile stocks in US Market | 17.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BRKR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BRKR's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 7,765 | Frank Laukien | https://www.bruker.com |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
Bruker Corporation Fundamentals Summary
BRKR fundamental statistics | |
---|---|
Market Cap | US$10.67b |
Earnings (TTM) | US$274.90m |
Revenue (TTM) | US$2.51b |
38.8x
P/E Ratio4.3x
P/S RatioIs BRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BRKR income statement (TTM) | |
---|---|
Revenue | US$2.51b |
Cost of Revenue | US$1.22b |
Gross Profit | US$1.29b |
Other Expenses | US$1.01b |
Earnings | US$274.90m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 09, 2023
Earnings per share (EPS) | 1.87 |
Gross Margin | 51.30% |
Net Profit Margin | 10.97% |
Debt/Equity Ratio | 121.2% |
How did BRKR perform over the long term?
See historical performance and comparison